Antiretroviral Drug Discovery Targeting the HIV-1 Nef Virulence Factor.
Lori A Emert-SedlakHaibin ShiColin M TiceLi ChenJohn J AlvaradoSherry T ShuShoucheng DuCatherine E ThomasJay E WrobelAllen B ReitzThomas E SmithgallPublished in: Viruses (2022)
While antiretroviral drugs have transformed the lives of HIV-infected individuals, chronic treatment is required to prevent rebound from viral reservoir cells. People living with HIV also are at higher risk for cardiovascular and neurocognitive complications, as well as cancer. Finding a cure for HIV-1 infection is therefore an essential goal of current AIDS research. This review is focused on the discovery of pharmacological inhibitors of the HIV-1 Nef accessory protein. Nef is well known to enhance HIV-1 infectivity and replication, and to promote immune escape of HIV-infected cells by preventing cell surface MHC-I display of HIV-1 antigens. Recent progress shows that Nef inhibitors not only suppress HIV-1 replication, but also restore sufficient MHC-I to the surface of infected cells to trigger a cytotoxic T lymphocyte response. Combining Nef inhibitors with latency reversal agents and therapeutic vaccines may provide a path to clearance of viral reservoirs.
Keyphrases
- hiv infected
- antiretroviral therapy
- hiv positive
- human immunodeficiency virus
- hiv aids
- hiv infected patients
- induced apoptosis
- cell cycle arrest
- hiv testing
- drug discovery
- men who have sex with men
- endoplasmic reticulum stress
- sars cov
- escherichia coli
- pseudomonas aeruginosa
- staphylococcus aureus
- signaling pathway
- immune response
- south africa
- squamous cell carcinoma
- drug delivery
- bipolar disorder
- young adults
- small molecule
- high throughput
- water quality
- pi k akt
- smoking cessation